{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "For 2023, the Degree Program Segment's adjusted EBITDA increased by $33.972 million (from $180.727 million to $214.699 million), and the Alternative Credential Segment's adjusted EBITDA improved by $11.743 million (from $(55.646) million to $(43.903) million).", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "In 2023, the Degree Program Segment did not record any impairment charges for goodwill, while the Alternative Credential Segment recorded $62.8 million in impairment charges. In 2022, the Degree Program Segment recorded $28.8 million in impairment charges, and the Alternative Credential Segment recorded $50.2 million in impairment charges. Therefore, the impairment charges for goodwill in the Alternative Credential Segment increased by $12.6 million from 2022 to 2023, while the Degree Program Segment saw no impairment charges in 2023.", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "In 2023 compared to 2022:\n\n- **Degree Program Segment**: FCE enrollments decreased from 233,635 to 194,574, a decline of 39,061.\n- **Alternative Credential Segment**: FCE enrollments increased from 93,471 to 97,647, an increase of 4,176.", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": "The main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021, were:\n\n1. **Divestitures**: Loss of gross profit from divested businesses ($33.5 million).\n2. **Cost Inflation and Supply Chain Pressures**: Increased costs due to inflation and supply chain issues.", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": "For the year ended December 31, 2022, impairment charges on property and equipment decreased to $18 from $788 in 2021. Amortization expense related to intangible assets increased to $15,480 from $10,469 in 2021.", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "For the year ended December 31, 2022, the operating income for the Healthcare Solutions segment decreased from $69,358 thousand to $25,812 thousand, and for the Industrial Solutions segment, it decreased from $48,555 thousand to $22,837 thousand, compared to the same period in 2021.", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "Block, Inc. earned $153.5 million in interest income from customer funds in 2023, which was immaterial in 2022 and 2021.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "In the fourth quarter of 2023, Block, Inc. reorganized its management reporting structure and moved the business activities and financial results of its BNPL platform fully under the Cash App segment. Previously, the financial results from the BNPL platform were equally allocated between the Cash App and Square segments. This change allows for better focus on consumer-based commerce and the development of financial tools within Cash App. As a result, the segment results now include the full financial results of the BNPL platform within the Cash App segment, rather than splitting them.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "As of January 31, 2022, the Company acquired consumer receivables from Afterpay with a fair value of $1,245,508,000. By December 31, 2023, the total amortized cost of consumer receivables was $2,629,969,000, with an allowance for credit losses of $185,275,000. The allowance for credit losses increased by $111,441,000 from the acquisition date to December 31, 2023, primarily due to the provision for credit losses of $261,296,000, offset by charge-offs and other adjustments of $228,845,000, and a foreign exchange effect of $1,534,000.", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "The net property and equipment values for C.H. Robinson Worldwide, Inc. decreased by 9.2% from $159,432,000 as of December 31, 2022, to $144,718,000 as of December 31, 2023.", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "The primary factors affecting C.H. Robinson's financial performance in 2023 were:\n\n1. **Weak Freight Demand and Excess Carrier Capacity**: This led to lower transportation rates and volumes, particularly in truckload and ocean services.\n2. **Decline in Revenues and Adjusted Gross Profits**: Total revenues decreased by 28.7% and adjusted gross profits decreased by 27.5%, driven by lower pricing and freight costs.\n3. **Increased Interest Expense**: Interest expense increased by $13.1 million due to higher average variable interest rates.\n4. **Foreign Currency Fluctuations**: The company experienced a net loss from foreign currency revaluation and realized foreign currency gains and losses, primarily due to the devaluation of the Argentine Peso.\n5. **Cost Optimization Efforts**: Personnel expenses decreased by 14.9% due to lower average employee headcount and reduced variable compensation.\n6. **Restructuring Charges**: The company incurred $17.5 million in additional restructuring charges, primarily related to workforce reductions.\n7. **Tax Settlements and Rate Changes**: An additional $19.2 million in tax expense was recognized due to a settlement related to the Section 199 domestic production activities deduction, and the effective tax rate increased to 20.5% from 19.4% in 2022.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "The revenue recognized for in-transit shipments decreased from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023. This decline is attributed to macroeconomic and industry factors impacting the cost of purchased transportation.", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "For the year ended December 31, 2023, Exact Sciences Corporation's total stock-based compensation expense was $231.3 million. As of the same date, the unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "Research and development expenses increased by $32.5 million (from $393.4 million in 2022 to $425.9 million in 2023) primarily due to higher personnel expenses and facility and support services. Sales and marketing expenses decreased by $118.9 million (from $846.0 million in 2022 to $727.1 million in 2023) mainly due to reduced direct marketing costs, professional fees, personnel expenses, and facility and support services.", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporation’s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "At the end of 2023, Exact Sciences Corporation had $605.4 million in cash and cash equivalents, compared to $242.493 million at the beginning of the year. This increase was primarily due to:\n\n1. **Net cash provided by operating activities**: $156.1 million.\n2. **Net cash provided by investing activities**: $49.7 million.\n3. **Net cash provided by financing activities**: $159.8 million.\n\nThese positive cash flows contributed to the significant increase in cash and cash equivalents.", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "Esperion's net product sales increased by $22.4 million (from $55.9 million in 2022 to $78.3 million in 2023), and their collaboration revenue increased by $18.4 million (from $19.6 million in 2022 to $38.0 million in 2023).", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023. Key factors contributing to this change included:\n\n- **Increase in Product Sales**: Net product sales increased from $55.9 million in 2022 to $78.3 million in 2023.\n- **Increase in Collaboration Revenue**: Collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023.\n- **Decrease in Research and Development Expenses**: R&D expenses decreased from $118.9 million in 2022 to $86.1 million in 2023, primarily due to reduced costs from the CLEAR Outcomes study.\n- **Increase in Selling, General, and Administrative Expenses**: SG&A expenses increased from $109.1 million in 2022 to $142.5 million in 2023, mainly due to higher legal costs and increased headcount.\n- **Slight Increase in Interest Expense**: Interest expense increased from $56.8 million in 2022 to $59.0 million in 2023, primarily due to additional interest expense from the Revenue Interest Purchase Agreement (RIPA) with Oberland.\n- **Increase in Other Income**: Other income, net, increased from $2.7 million in 2022 to $5.3 million in 2023, mainly due to higher interest income on investments.\n\nThese factors collectively contributed to the reduction in net loss.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, an increase of $22.4 million. Collaboration revenue also increased from $19.6 million in 2022 to $38.0 million in 2023, an increase of $18.4 million.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "For the Property & Casualty insurance vertical, the revenue decreased by 52.6% from 2021 to 2023. For the Health insurance vertical, the revenue decreased by 0.6% from 2021 to 2023.", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "In the year ended December 31, 2023, revenue from Open Marketplace transactions was $378.7 million, while revenue from Private Marketplace transactions was $9.4 million.", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue from $224.4 million in 2022 to $164.2 million in 2023, a decline of $60.2 million or 26.8%, was a significant contributor to the overall decline in total revenue. This reduction was due to lower customer acquisition spending by P&C carriers in response to reduced underwriting profitability.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "Regulatory changes in the EU, such as the proposed reduction in data exclusivity from eight to six years and the implementation of the Medical Devices Regulation (MDR), could significantly impact Mind Medicine's EU operations. The reduction in data exclusivity could shorten the period during which Mind Medicine can prevent competitors from using their clinical trial data, potentially leading to earlier market entry by generics or biosimilars. The MDR introduces stricter requirements for medical device development, including more comprehensive clinical evaluations and post-market surveillance, which could increase costs and delay product launches. Both changes could affect Mind Medicine's competitive position and market access in the EU.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "Between December 31, 2022, and December 31, 2023, the company issued $100.2 million worth of equity securities under the shelf registration statement. However, this calculation is based on the difference between the $99.8 million remaining available for issuance as of December 31, 2023, and the $200.0 million initially registered. \n\nTo be precise:\n- Initial registration: $200.0 million\n- Remaining as of December 31, 2023: $99.8 million\n- Amount issued: $200.0 million - $99.8 million = $100.2 million", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "If MindMed fails to comply with controlled substance laws and regulations, potential consequences include:\n\n- Significant fines and penalties\n- Administrative sanctions \n- Convictions or settlements\n- Loss of regulatory approvals\n- Damage to reputation and ability to conduct business\n- Increased costs to investigate or defend against enforcement actions\n- Prohibitions on business activities\n- Criminal charges against key executives\n- Seizure of corporate assets\n- Inability to continue business operations\n\nThe company notes these risks apply to its development activities involving controlled substances like lysergide and MDMA, which are currently Schedule I drugs. Compliance is complex and failure to comply could have material adverse effects on the business.", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "In fiscal year 2024, a single customer within the Compute & Networking segment generated 13% of NVIDIA's total revenue. This concentration poses challenges such as:\n\n- **Revenue Dependency:** High dependence on a single customer can make NVIDIA vulnerable to any changes in that customer's purchasing patterns or financial health.\n- **Market Risk:** If the customer reduces orders or faces business difficulties, it could significantly impact NVIDIA's revenue and financial performance.\n- **Negotiating Power:** The customer may have significant leverage in negotiations, potentially affecting pricing and terms of supply.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "NVIDIA's net income increased from $4.368 billion in January 29, 2023, to $29.760 billion in January 28, 2024, representing an increase of $25.392 billion. The revenue increased from $26.974 billion to $60.922 billion during the same period, representing an increase of $33.948 billion.", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "In fiscal year 2024, a single customer in the Compute & Networking segment accounted for 13% of NVIDIA's total revenue. This demonstrates a risk of customer concentration, as losing or having a significant reduction in purchases from this key customer could harm NVIDIA's financial condition and results of operations.", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": false, "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": false, "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": false, "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "In 2023, automotive sales revenue increased by $11.30 billion (17%) compared to 2022, primarily due to a 473,382 increase in combined Model 3 and Model Y deliveries globally. However, this increase was partially offset by a lower average selling price due to overall price reductions, sales mix, and the U.S. dollar strengthening against other foreign currencies.\n\nThe gross margin for total automotive decreased from 28.5% to 19.4%, mainly due to the lower average selling price of vehicles, which was partially offset by a favorable change in the average combined cost per unit and the benefit from IRA manufacturing credits.", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "As of December 31, 2023, Tesla's short-term investments increased from $5,932 million to $12,696 million, and its inventory increased from $12,839 million to $13,626 million.", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "As of December 31, 2023, Tesla's commitments in the state of New York include spending $5.00 billion in combined capital, operational expenses, costs of goods sold, and other costs by December 31, 2029. For Shanghai, China, Tesla is required to spend RMB 14.08 billion (approximately $2.03 billion) in capital expenditures by the end of 2023, which has been achieved, and to generate RMB 2.23 billion (approximately $0.32 billion) in annual tax revenues starting at the end of 2023.", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
